Deininger K, Korf P, Lauber L, Grimm R, Strecker R, Steinacker J, Lisson CS, Mühling BM, Schmidtke-Schrezenmeier G, Rasche V, Speidel T, Glatting G, Beer M, Beer AJ, Thaiss W. From Phantoms to Patients: Improved Fusion and Voxel-Wise Analysis of Diffusion-Weighted Imaging and FDG-Positron Emission Tomography in Positron Emission Tomography/Magnetic Resonance Imaging for Combined Metabolic–Diffusivity Index (cDMI). Diagnostics 2024; 14: 1787.
Grunert M, Schenke SA, Konrad A, Schütze C, Förster S, Klemenz B, Stahl AR. Thyroid scintigraphy: establishing a clinically useful normal range for 99mTc pertechnetate uptake. Nuklearmedizin 2024; 63(06): 337-346.
Hardiansyah D, Riana A, Eiber M, Beer AJ, Glatting G. Population-based model selection for an accurate estimation of time-integrated activity using a non-linear mixed-effects modelling. Z Med Phys 2024; epub 20.02.2023.
Hardiansyah D, Yousefzadeh-Nowshahr E, Kind F, Beer A, Ruf J, Glatting G, Mix M. Single-time-point renal dosimetry using non-linear mixed-effects modelling and population-based model selection in [177Lu]Lu-PSMA-617 Therapy. J Nucl Med. In press Feb. 17, 2024.
Harms M, Haase A, Rodríguez-Alfonso A, Löffler J, Almeida-Hernández Y, Ruiz-Blanco YB, Albers D, Gilg A, von Bank F, Zech F, Groß R, Datta M, Jaikishan J, Draphoen B, Habib M, Ständker L, Wiese S, Lindén M, Winter G, Rasche V, Beer AJ, Jumaa H, Abadi AH, Kirchhoff F, Busch M, Dünker N, Sanchez-Garcia E, Münch J. Fatty acid conjugated EPI-X4 derivatives with increased activity and in vivo stability. J Control Release 2024; 373: 583-98.
Kiess AP, O'Donoghue J, Uribe C, Bodei L, Hobbs RF, Hesterman J, et al. How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design. Journal of Clinical Oncology;0:JCO.23.01241
Ivashchenko OV, O'Doherty J, Hardiansyah D, Cremonesi M, Tran-Gia J, Hippeläinen E, Stokke C, Grassi E, Sandström M, Glatting G. Time-Activity data fitting in molecular radiotherapy: Methodology and pitfalls. Phys Med 2024; 117:103192.
Patrianesha BB, Peters SMB, Hardiansyah D, Ritawidya R, Privé BM, Nagarajah J, Konijnenberg MW, Glatting G. Single-time-point dosimetry using model selection and the Bayesian fitting method: A proof of concept. Physica Medica 2025; Volume 129, 104868.
Sollmann N, Hoffmann G, Schramm S, Reichert M, Hernandez Petzsche M, Strobel J, Nigris L, Kloth C, Rosskopf J, Börner C, Bonfert M, Berndt M, Grön G, Müller HP, Kassubek J, Kreiser K, Koerte IK, Liebl H, Beer A, Zimmer C, Beer M, Kaczmarz S. Arterial Spin Labeling (ASL) in Neuroradiological Diagnostics - Methodological Overview and Use Cases. Röfo 2024; 196(1): 36-51.
Strobel J, Yousefzadeh-Nowshahr E, Deininger K, Bohn KP, von Arnim CAF, Otto M, Solbach C, Anderl-Straub S, Polivka D, Fissler P, Glatting G, Riepe MW, Higuchi M, Beer AJ, Ludolph A, Winter G. Exploratory Tau PET/CT with [11C]PBB3 in Patients with Suspected Alzheimer’s Disease and Frontotemporal Lobar Degeneration: A Pilot Study on Correlation with PET Imaging and Cerebrospinal Fluid Biomarkers. Biomedicines 2024; 12: 1460.
Subangun R. M., Hardiansyah D., Ibrahim R. F. I., Patrianesha B- B., Hidayati N. R., Beer A. J., Glatting G. Few-time-points time-integrated activity coefficients calculation using non-linear mixed-effects modeling: Proof of concept for [111In]In-DOTA-TATE in kidneys. Physica Medica 2025; Volume 129, 104865.
Vasić V, Gustafsson J, Nowshahr EY, Stenvall A, Beer AJ, Gleisner KS, Glatting G. A PBPK model for PRRT with [177Lu]Lu-DOTA-TATE: Comparison of model implementations in SAAM II and MATLAB/SimBiology. Phys Med 2024; 119: 103299
